CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
-2.44%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$1.71B
AUM Growth
+$1.71B
(-0.75%)
Cap. Flow
+$64.3M
Cap. Flow
% of AUM
3.76%
Top 10 Holdings %
Top 10 Hldgs %
63.62%
Holding
35
New
7
Increased
9
Reduced
6
Closed
6
Top Buys
| 1 |
HCA Healthcare
HCA
|
$81.1M |
| 2 |
Gilead Sciences
GILD
|
$67.6M |
| 3 |
Viatris
VTRS
|
$66.6M |
| 4 |
United Therapeutics
UTHR
|
$28.7M |
| 5 |
DaVita
DVA
|
$28.1M |
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$95.3M |
| 2 |
Biogen
BIIB
|
$94.6M |
| 3 |
NUVA
NuVasive, Inc.
NUVA
|
$42.6M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$37.2M |
| 5 |
MDCO
Medicines Co
MDCO
|
$28.1M |
Sector Composition
| 1 | Healthcare | 94.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $209M | 9.76% | 1,250,000 -50,000 | -4% | -$8.37M |
|
|
2
Viatris
VTRS
$12.3B
| $176M | 8.21% | 9,250,000 +3,500,000 | +61% | +$66.6M |
|
|
3
DaVita
DVA
$9.85B
| $113M | 5.24% | 2,000,000 +500,000 | +33% | +$28.1M |
|
4
Perrigo
PRGO
$3.27B
| $95.2M | 4.44% | 2,000,000 -100,000 | -5% | -$4.76M |
|
5
Brookdale Senior Living
BKD
$1.83B
| $90.1M | 4.2% | 12,500,000 +1,500,000 | +14% | +$10.8M |
|
6
Nektar Therapeutics
NKTR
$568M
| $89M | 4.15% | 2,500,000 +500,000 | +25% | +$17.8M |
|
7
Universal Health Services
UHS
$11.6B
| $84.8M | 3.95% | 650,000 | – | – |
|
|
8
HCA Healthcare
HCA
$94.5B
| $81.1M | 3.78% | +600,000 | New | +$81.1M |
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $76M | 3.54% | 500,000 | – | – |
|
10
Ascendis Pharma
ASND
$11.8B
| $74.8M | 3.49% | 650,000 +220,000 | +51% | +$25.3M |
|
|
11
Gilead Sciences
GILD
$140B
| $67.6M | 3.15% | +1,000,000 | New | +$67.6M |
|
|
MDCO
12
DELISTED
Medicines Co
MDCO
| $62M | 2.89% | 1,700,000 -771,523 | -31% | -$28.1M |
|
13
Teva Pharmaceuticals
TEVA
$21.1B
| $60M | 2.8% | 6,500,000 +3,000,000 | +86% | +$27.7M |
|
14
Zymeworks
ZYME
$1.12B
| $57.2M | 2.67% | 2,600,000 +434,000 | +20% | +$9.55M |
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $52.4M | 2.44% | 400,000 -200,000 | -33% | -$26.2M |
|
16
Tenet Healthcare
THC
$16.3B
| $51.7M | 2.41% | 2,500,000 +750,000 | +43% | +$15.5M |
|
17
Bristol-Myers Squibb
BMY
$96B
| $45.4M | 2.11% | 1,000,000 -100,000 | -9% | -$4.54M |
|
|
MNTA
18
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $43.6M | 2.03% | 3,500,000 -500,000 | -13% | -$6.23M |
|
19
Atara Biotherapeutics
ATRA
$84.6M
| $40.2M | 1.87% | 2,000,000 | – | – |
|
|
AMAG
20
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $30M | 1.4% | 3,000,000 +350,000 | +13% | +$3.5M |
|
|
21
United Therapeutics
UTHR
$13.8B
| $28.7M | 1.34% | +367,529 | New | +$28.7M |
|
|
THOR
22
DELISTED
Synthorx, Inc. Common Stock
THOR
| $25.2M | 1.17% | 1,862,116 | – | – |
|
23
GSK
GSK
$79.9B
| $20M | 0.93% | +500,000 | New | +$20M |
|
24
Cyclerion Therapeutics
CYCN
$7.91M
| $17.9M | 0.83% | +1,561,915 | New | +$17.9M |
|
25
TG Therapeutics
TGTX
$4.65B
| $8.65M | 0.4% | +1,000,000 | New | +$8.65M |
|